{'52WeekChange': 0.70710385,
 'SandP52WeekChange': None,
 'address1': '333 Allerton Avenue',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 92.31,
 'askSize': 800,
 'averageDailyVolume10Day': 304575,
 'averageVolume': 711546,
 'averageVolume10days': 304575,
 'beta': 2.284117,
 'beta3Year': None,
 'bid': 92.23,
 'bidSize': 1100,
 'bookValue': 7.489,
 'category': None,
 'circulatingSupply': None,
 'city': 'South San Francisco',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 94.423,
 'dayLow': 91.26,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -12.617,
 'enterpriseToRevenue': None,
 'enterpriseValue': 4007400192,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 96.09543,
 'fiftyTwoWeekHigh': 126.301,
 'fiftyTwoWeekLow': 42.65,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 45402687,
 'forwardEps': -6.6,
 'forwardPE': -13.972728,
 'fromCurrency': None,
 'fullTimeEmployees': 246,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.03787,
 'heldPercentInstitutions': 1.07995,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/myokardia.com',
 'longBusinessSummary': 'MyoKardia, Inc., a clinical stage biopharmaceutical '
                        'company, discovers, develops, and commercializes '
                        'targeted therapies for the treatment of serious and '
                        'neglected rare cardiovascular diseases. Its lead '
                        'product candidate is mavacamten, an orally '
                        'administered small molecule, which is in Phase III '
                        'clinical trial that is designed to reduce left '
                        'ventricular contractility to alleviate the functional '
                        'consequences and symptoms of obstructive hypertrophic '
                        'cardiomyopathy (HCM) and prevent or reverse HCM '
                        'progression, as well as in Phase II clinical trial '
                        'for non-obstructive HCM. The company also develops '
                        'MYK-491, an orally-administered small molecule, which '
                        'is in Phase IIa clinical trial that is designed to '
                        'restore normal cardiac muscle contractility in the '
                        'diseased dilated cardiomyopathy (DCM) heart. Its '
                        'preclinical programs include MYK-224, a HCM-targeting '
                        'candidate that is designed to reduce excess cardiac '
                        'contractility and enhance diastolic function; LUS-1, '
                        'which is used to counteract a muscle abnormality that '
                        'results in impaired relaxation of the left ventricle; '
                        'and ACT-1 targeting genetic DCM due to sarcomeric '
                        'mutations and impaired calcium regulation. The '
                        'company has a collaboration with 23andMe, Inc., a '
                        'consumer genetics and research company; and a '
                        'strategic collaboration and license agreement with '
                        'Fulcrum Therapeutics, Inc. to discover, develop and '
                        'commercialize novel targeted therapies for the '
                        'treatment of genetic cardiomyopathies. Myokardia, '
                        'Inc. was founded in 2012 and is headquartered in '
                        'South San Francisco, California.',
 'longName': 'MyoKardia, Inc.',
 'market': 'us_market',
 'marketCap': 4304903680,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_217502341',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -308611008,
 'nextFiscalYearEnd': 1640908800,
 'open': 93.04,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': -0.83,
 'phone': '650 741 0900',
 'previousClose': 93.72,
 'priceHint': 2,
 'priceToBook': 12.314061,
 'priceToSalesTrailing12Months': None,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 94.423,
 'regularMarketDayLow': 91.26,
 'regularMarketOpen': 93.04,
 'regularMarketPreviousClose': 93.72,
 'regularMarketPrice': 93.04,
 'regularMarketVolume': 286151,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 46680800,
 'sharesPercentSharesOut': 0.1093,
 'sharesShort': 5102157,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 4375011,
 'shortName': 'MyoKardia, Inc.',
 'shortPercentOfFloat': 0.3321,
 'shortRatio': 10.54,
 'startDate': None,
 'state': 'CA',
 'strikePrice': None,
 'symbol': 'MYOK',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -6.668,
 'twoHundredDayAverage': 76.236725,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': 'eaba7f0f-d742-36d3-b560-764813abb49f',
 'volume': 286151,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.myokardia.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '94080'}